Krajska zdravotni a.s.
- Address
- lock Available on a paid plan
Immune System Diseases
The team at Krajska zdravotni a.s. investigates therapies that strengthen immune defenses, aiming to reduce serious infections in patients with low antibody levels or receiving B‑cell depleting treatments.
- Prevention of major infections in hypogammaglobulinemia
- Safety and efficacy of B‑cell depletion therapy
- Evaluation of Panzyga (IVIG) for infection prophylaxis
- Novel immunomodulatory agents in autoimmune conditions
With 17 active trials and 22 investigators, the site in Teplice, Czechia contributes to advancing care for patients with compromised immune systems.
Musculoskeletal Diseases
Researchers are developing regenerative approaches for joint damage, testing whether stem‑cell enriched scaffolds improve healing of knee cartilage lesions.
- Autologous MSC‑seeded 3D scaffolds combined with microfracture
- Bone‑marrow derived stem cell therapy for cartilage repair
- Comparison of scaffold‑only vs. cell‑enhanced techniques
- Clinical outcomes of chondral defect regeneration
The program leverages the hospital’s orthopedic expertise to explore innovative treatments that could restore joint function and reduce pain.
Nervous System Diseases
The centre conducts extensive studies on multiple sclerosis, evaluating new drugs that may slow disease activity, lessen relapses, and improve neurological function across its various forms.
- Relapsing‑remitting multiple sclerosis therapies
- Primary progressive multiple sclerosis interventions
- Secondary progressive multiple sclerosis trials
- Myelin oligodendrocyte glycoprotein antibody‑associated disease (MOG‑AD) research
- Spasticity management in MS patients
Across the neurological portfolio, 17 trials address disease progression, relapse reduction, and quality‑of‑life improvements for patients living with chronic neuro‑inflammatory conditions.
Skin and Connective Tissue Diseases
Although fewer studies target skin directly, the site supports investigations into connective‑tissue manifestations that often accompany systemic autoimmune disorders.
- Connective tissue involvement in autoimmune disease trials
- Monitoring skin‑related adverse events during immunotherapy
- Biomarker evaluation for connective tissue disease activity
This research helps clinicians better understand and manage the dermatologic and connective‑tissue aspects of complex immune‑mediated illnesses.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 12 therapeutic areas and 15 of 113 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 110 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 19 by active trials.
- 1F. Hoffmann-La Roche AG2active
lock +18 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG5trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Krajska zdravotni a.s.
lock Showing 1 of 46 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis | Biogen Idec Research Limited | Phase II | Not Recruiting | Oct 2023 | Feb 2026 |
IMP list
lock Showing 1 of 113 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ocrelizumab | 4 | Unknown | 2022-03-28 | 2025-09-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.